AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05403866
Drug: LT3001 Drug Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT05403866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT06754475
Drug: Standart medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standart medical teatment
Trial: NCT04934059
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5g/ tablet
Trial: NCT06749665
Drug: polidacanol 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aethoxysklerol 3%,60mg/ ml ampoule, kreussler pharma, Germany
Trial: NCT06755515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: placebo Description: iv, every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles.
Trial: NCT05977023
Drug: Placebo Cap
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of placebo as a comparator.
Trial: NCT05228431
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting from the first day of radiotherapy (set as day 0), the patient received a total of 4 courses of XELOX chemotherapy on days -42, -21, 42, and 63, including oxaliplatin 130 mg/m2, intravenous administration, d1, repeat every 3 weeks; and capecitabine 1000mg/m2, twice daily, d1-d14, repeat every 3 weeks.
Trial: NCT05228431
Drug: Capecitabine monotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During radiotherapy (Monday to Friday), capecitabine was administered at 1650 mg/m2/d, twice a day.
Trial: NCT06758557
Drug: HB0025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB0025 IV every 3 weeks (q3w)
Trial: NCT06757504
Drug: Placebo (Simulant TTYP01 Tablets)
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
Trial: NCT06757712
Drug: medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The medical treatment will be received for 12 weeks.
Trial: NCT06759623
Drug: Different drug type for conduction of general anesthesia
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly divided into two groups: patients for whom general anesthesia will be performed with sevoflurane and patients for whom general anesthesia will be performed with desflurane.
Trial: NCT06758830
Drug: Consolidation Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX: Oxaliplatin 130 mg/m² (day 1) + capecitabine 1000 mg/m² (days 1-14), every 3 weeks for 4 cycles.~Or FOLFOX: Oxaliplatin - 85 mg/m2 intravenously (2-hour infusion), drip for 1 day. Calcium folinate (folinic acid) - 400 mg/m2/d. intravenously (2-hour infusion), started on day 1. F(5-fluorouracil) - 400 mg/m2/d. intravenously (bolus), started on day 1. Repeat every 2 weeks for 6 times.
Trial: NCT06760065
Drug: Susceptibility-Guided Quadruple Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this arm will receive quadruple therapy tailored to individual H. pylori resistance profiles, including a proton pump inhibitor (Esomeprazole 20 mg), Bismuth Potassium Citrate 220 mg, and two antibiotics selected based on susceptibility testing (e.g., Amoxicillin, Clarithromycin, Metronidazole, Levofloxacin, or Furazolidone). The regimen is administered for 14 days to optimize eradication outcomes.
Trial: NCT06759090
Drug: Metronomic capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronomic capecitabine: 650 mg/m2, twice daily, to be swallowed with water within 30 minutes after a meal;
Trial: NCT06760078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous placebo (10mL NS, diluted in 90mL NS) matching the specification and appearance of TXA will be administered as an initial bolus over 10 minutes, followed by a continuous infusion of placebo (10mL NS, diluted in 240mL NS) over 8 hours, with intensive blood pressure lowering maintained throughout the treatment period and continued until 24 hours after symptoms onset.
Trial: NCT04631536
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc)
Trial: NCT06582485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
Trial: NCT06170216
Drug: immunochemotherapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observing different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), which are chosen by investigators, such as RCHOP, BR, RCVP, etc.
Trial: NCT06749418
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local heating: eplerenone is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response.
Trial: NCT06456580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT06427850
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive an injection of Normal saline into the surgical site
Trial: NCT05134363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: equal volume of normal saline
Trial: NCT06221826
Drug: Mexidol
RxNorm normalized name: Brexidol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurocytoprotector
Trial: NCT04940624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat placebo-matching mini-tablets or tablets.
Trial: NCT06253806
Drug: Placebo Sham Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The stellate ganglion will be identified using ultrasound guidance, and after negative aspiration, 6-8 mL of 0.9% saline will be injected near the stellate ganglion.
Trial: NCT06625957
Drug: NTCB02-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 Days infusion
Trial: NCT06625957
Drug: NTCB-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 Days infusion
Trial: NCT06769620
Drug: ORT247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORT247 will be provided to study sites in single-use, sterile vials for infusion. Each dose will be prepared with normal saline for infusion.
Trial: NCT06769620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo consists of normal saline
Trial: NCT06759857
Drug: FHND9041
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FHND9041 is a novel therapeutic agent targeting EGFR mutations. Participants will take an 80 mg oral dose once daily until disease progression, intolerable toxicity, or meeting other study-defined discontinuation criteria.
Trial: NCT06759649
Drug: COM503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion
Trial: NCT06758596
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A capsule that contains only dextrose filler administered during the first or second laboratory visit.
Trial: NCT06762145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 3 days started from the day on TAVR
Trial: NCT06773117
Drug: High dose Susu Xiao'er Zhike Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Susu Xiao'er Zhike Granules 1 bag(7g granule per bag,contains 20.25 g crude herbs), twice a day for five days
Trial: NCT06773117
Drug: Extremely-low dose Susu Xiao'er Zhike Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extremely-low dose Susu Xiao'er Zhike Granules 1 bag (7g granule per bag,contains 1.01 g crude herbs), twice a day for five days
Trial: NCT05578846
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.
Trial: NCT05578846
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.
Trial: NCT04339036
Drug: Capecitabine Oral Product
RxNorm normalized name: capecitabine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 750 mg/m2 twice daily orally for 14 days
Trial: NCT06724640
Drug: VH4011499 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH4011499 Injection will be administered either subcutaneously or intramuscularly.
Trial: NCT06724640
Drug: Placebo for VH4011499 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for VH4011499 Injection will be administered either subcutaneously or intramuscularly.
Trial: NCT06118372
Drug: Recombinant von Willebrand Factor
RxNorm normalized name: VON WILLEBRAND FACTOR,RECOMBINANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant von Willebrand Factor is a drug that is currently FDA approved to treat patients with certain types of von Willebrand Disease. In the current trial it will be used to treat ECMO patients who have acquired von Willebrand syndrome.
Trial: NCT05596045
Drug: ASC10
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
Trial: NCT05596045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive placebo
Trial: NCT05717686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered
Trial: NCT06754761
Drug: [14C] AZD6738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radiolabeled AZD6738 / ceralasertib
Trial: NCT06423703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three times per day 3 days (with cebranopadol), four times per day for 3 days (placebo arm)
Trial: NCT06055231
Drug: Marijuana via vape device
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given via vape device
Trial: NCT06055231
Drug: Marijuana via joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given via joint
Trial: NCT05262023
Drug: DNL593
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
Trial: NCT05262023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
Trial: NCT06755242
Drug: GNC-077
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT06373653
Drug: Manzanilla Sophia®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matricaria recutita 0.025%, Ophthalmic solution.
Trial: NCT06373653
Drug: Meticel Ofteno®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypromellose 0.5%, Ophthalmic solution.
Trial: NCT06035978
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verospiron (Spironolactone) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
Trial: NCT05799755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT05799755
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.
Trial: NCT04564326
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between.
Trial: NCT05022212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered vaginally
Trial: NCT06551233
Drug: 9MW2821
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be evaluated from low dose to high dose through intravesical therapy and then select the suitable doses to expand according to study data.
Trial: NCT06602479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume-matched placebo for all arms
Trial: NCT04699279
Drug: Rosuvastatin 10mg
RxNorm normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 10mg is taken by oral or nasal feeding every day at ang time.
Trial: NCT06673368
Drug: NRCT-101SR, NRCT-202XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRCT-101SR in combination with NRCT-202XR or NRCT-202XR alone
Trial: NCT05335317
Drug: Topical hormone estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estriol suppository ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Active ingredient of 0.5 milligram in 1 suppository. Daily dose will be 1 suppository.
Trial: NCT06374485
Drug: AU409 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06767007
Drug: PD1
RxNorm normalized name: STATLOCK UNIVERSAL PLUS LG VUPD1214
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PD-1 monoclonal antibody used is Sintilimab 200mg every 3 weeks
Trial: NCT06767007
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy regimen of rectal cancer, using a second-line regimen primarily based on fluorouracil, such as a tri-weekly CAPOX or a bi-weekly mFOLFOX6/FOLFIRI/FOLFOXIRI + targeted therapy
Trial: NCT06454747
Drug: SM-030 gel 0.64%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application to face twice daily for 12 weeks.
Trial: NCT04759807
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.
Trial: NCT04759807
Drug: PUR1800 250 ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 250 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
Trial: NCT04759807
Drug: PUR1800 500 ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 500 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
Trial: NCT06764147
Drug: ET-26HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
Trial: NCT06790927
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The doctor prescribes medication for patients and follow-up every 3 months
Trial: NCT06454747
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application to face twice daily for 12 weeks.
Trial: NCT06101160
Drug: onaBoNT-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection under ultrasonography
Trial: NCT06454747
Drug: SM-030 gel 0.08%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application to face twice daily for 12 weeks.
Trial: NCT06790927
Drug: Standard Medical Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard treatment group was followed up monthly, Amlodipine 5 mg is preferred for selected patients, and amlodipine 5 mg + irbesartan 150mg is used for those who do not meet blood pressure targets after 4 weeks treatment, amlodipine 10mg + irbesartan 300mg is used for those who do not meet blood pressure targets after one month, for those whose blood pressure is still not up to standard after 4 weeks will be treated with amlodipine 10mg + irbesartan 300mg + hydrochlorothiazide 12.5mg.
Trial: NCT06764940
Drug: Utidelone in combination with capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: UTD1 25 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
Trial: NCT06764940
Drug: Utidelone in combination with capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
Trial: NCT06764940
Drug: Utidelone in combination with capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Utidelone 25 mg/m2/d or 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
Trial: NCT06762548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo solution
Trial: NCT06596356
Drug: [14C] TS-172
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single dose of about 30 mg of TS-172 containing 1 MBq \[14C\]TS-172 as an oral solution
Trial: NCT04962139
Drug: ON101 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
Trial: NCT04968184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will orally receive placebo matching to KBP-5074 tablets QD.
Trial: NCT05322616
Drug: JK07
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
Trial: NCT05322616
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control
Trial: NCT06772766
Drug: 9MW3011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending IV doses administered per protocol
Trial: NCT06772766
Drug: 9MW3011 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending IV doses administered per protocol
Trial: NCT06361329
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT02465138
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac
Trial: NCT02465138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline
Trial: NCT02201381
Drug: Metabolic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: While subjects are being treated with the four metabolic drugs, every 3 months they will bring in their medical records and data will be collected to determine the effect of the intervention
Trial: NCT06281951
Drug: Fentanyl - Inhalation by facial nebulization
RxNorm normalized name: fentanyl Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 administrations based on a weight-dependent threshold (40 µg per administration for a weight \< 70kg and 50 µg per administration for a weight ≥ 70kg).
Trial: NCT06281951
Drug: Fentanyl - Nebulisation
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 administrations based on a weight-dependent threshold (20 µg/administration and for a weight \< 70kg and 30 µg/administration for a weight ≥ 70kg). The dose of each bolus will be distributed at equivalent volume in both nasal pits
Trial: NCT06782594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, iv, bid, for 3 to 5 days